enVVeno Medical Corporation

NasdaqCM:NVNO Stock Report

Market Cap: US$59.8m

enVVeno Medical Past Earnings Performance

Past criteria checks 0/6

enVVeno Medical's earnings have been declining at an average annual rate of -24.7%, while the Medical Equipment industry saw earnings growing at 12% annually. Revenues have been declining at an average rate of 105.5% per year.

Key information

-24.7%

Earnings growth rate

44.5%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate-105.5%
Return on equity-44.8%
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Here's Why We're Not Too Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Situation

Jun 26
Here's Why We're Not Too Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Situation

Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth

Mar 07
Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth

Will enVVeno Medical (NASDAQ:NVNO) Spend Its Cash Wisely?

Aug 14
Will enVVeno Medical (NASDAQ:NVNO) Spend Its Cash Wisely?

Is enVVeno Medical (NASDAQ:NVNO) In A Good Position To Deliver On Growth Plans?

Apr 22
Is enVVeno Medical (NASDAQ:NVNO) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

Dec 21
We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

enVVeno Medical: Unique Exposure To Venous Treatment Domain

Sep 23

We're Hopeful That enVVeno Medical (NASDAQ:NVNO) Will Use Its Cash Wisely

Aug 23
We're Hopeful That enVVeno Medical (NASDAQ:NVNO) Will Use Its Cash Wisely

enVVeno Medical reports Q2 results

Aug 03

We Think enVVeno Medical (NASDAQ:NVNO) Can Afford To Drive Business Growth

May 10
We Think enVVeno Medical (NASDAQ:NVNO) Can Afford To Drive Business Growth

We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

Jan 25
We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics

Sep 08

Hancock Jaffe Laboratories finance chief sheds interim tag

Dec 31

Hancock Jaffe approves 1:25 reverse stock split

Nov 27

Revenue & Expenses Breakdown

How enVVeno Medical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:NVNO Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-211212
30 Jun 240-211112
31 Mar 240-221113
31 Dec 230-241214
30 Sep 230-241213
30 Jun 230-251313
31 Mar 230-261412
31 Dec 220-251510
30 Sep 220-27199
30 Jun 220-24168
31 Mar 220-19146
31 Dec 210-17116
30 Sep 210-1266
30 Jun 210-1266
31 Mar 210-1155
31 Dec 200-1054
30 Sep 200-743
30 Jun 200-743
31 Mar 200-752
31 Dec 190-852
30 Sep 190-753
30 Jun 190-752
31 Mar 190-1371
31 Dec 180-1661
30 Sep 180-1870
30 Jun 180-1970
31 Mar 180-1261
31 Dec 170-851
30 Sep 171-750
30 Jun 171-540
31 Mar 171-640
31 Dec 161-650
30 Sep 160-540
31 Dec 150-110
31 Dec 140-110

Quality Earnings: NVNO is currently unprofitable.

Growing Profit Margin: NVNO is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NVNO is unprofitable, and losses have increased over the past 5 years at a rate of 24.7% per year.

Accelerating Growth: Unable to compare NVNO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NVNO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.4%).


Return on Equity

High ROE: NVNO has a negative Return on Equity (-44.84%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies